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Abstract
Background: Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable
oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10% and 30 to
50%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic
techniques is based on promising results, including lower postoperative morbidity rates, which are related to the
reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric
mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the
reduced surgical trauma.
Methods/Design: The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients
in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-
field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same
procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate
the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day
mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform
medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using
25 and 50 patients included in arm A.
Discussion: Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major
pulmonary complications, which are responsible for 50% of the postoperative deaths. This study represents the first
randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to
the postoperative course and oncological outcomes in oesophageal cancer surgery.
Trial Registration: NCT00937456 (ClinicalTrials.gov)
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Background
Surgery is viewed as the best treatment for resectable
thoracic oesophageal cancer (OC) with a 5-year survival
rate of around 40% in patients resected with a curative
intent [1,2]. Oesophagectomy using the abdominal and
right-thoracic approach (Ivor-Lewis procedure) is
considered to be the standard technique for middle- and
lower-third thoracic OC, which represent the most fre-
quent locations for OC, allowing for optimal loco-regio-
nal control and long-term survival. However, despite
advances in surgical and perioperative management,
postoperative morbidity, especially pulmonary complica-
tions, remains high and is reportedly between 30 and
50%, with a significant postoperative mortality between
2 and 10% [1].
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attempted during the last decade with the aim of
improving the postoperative outcomes without compro-
mising oncological outcomes. MIO corresponds to a
collection of techniques that combine thoracoscopic
and/or laparoscopic approaches, including hybrid MIO
(HMIO) (laparoscopy/thoracotomy or laparotomy/thora-
coscopy) and total MIO (laparoscopy/thoracoscopy).
These methods have had controversial impacts on the
postoperative course, and few data are available regard-
ing the oncological outcomes [3-5].
To date, no randomised trials have been published,
and the few retrospective comparative cohort studies
that are available are limited by small sample sizes [6-8],
major selection biases that make it impossible to com-
pare study groups [9] and/or an absence of a rigorous
definition of complications.
The thoracoscopic approach has received greater
attention than laparoscopy. In the systematic reviews
that have been published, thoracoscopic resections were
found to have marginal benefits over open resections,
such as reduced blood loss and transfusion rates and a
shorter hospital stay. However similar morbidity profiles
were observed, especially regarding pulmonary compli-
cations, which are the main postoperative complications
after oesophagectomy [3,4]. A multicentre randomised
trial (the TIME Trial) has recently been designed to
study the impact of MIO (thoracoscopy and laparoscopy
versus thoracotomy and laparotomy) in OC surgery, but
multiple surgical procedures are proposed and there is
an absence of perioperative care standardisation [10].
Laparoscopy has not been widely studied, although
this technique may offer several advantages, including a
lower rate of pulmonary complications (due to the less
invasive nature of the procedure and reduced deteriora-
tion of the ventilatory mechanism than is observed after
the open procedure [11]), ease of performance and
reproducibility in specialised and non-specialised cen-
tres, the absence of laparoscopic tumoural dissection
and the consequent applicability to a large number of
patients regardless of the tumoural stage or neoadjuvant
treatment and a lower risk of impairment of the oncolo-
gical outcomes.
Several retrospective studies have suggested that
HMIO with laparoscopic gastric mobilisation is feasible
in OC, but these studies have major flaws, such as non-
comparable groups, a small number of enrolled patients,
the lack of a control group and neither pulmonary com-
plications nor long-term outcomes considered as pri-
mary endpoints [12-16].
Because the vast majority of published studies have
placed a higher priority on demonstrating feasibility
than evaluating the impact on patients, and because of
inconclusive results regarding the benefits of MIO with
respect to outcomes, we aim to test the hypothesis that
HMIO based on laparoscopic gastric mobilisation and
open thoracotomy decreases major postoperative mor-
bidity without compromising oncological outcomes
through a large prospective randomised controlled trial.
Methods/Design
1- Protocol overview (Figure 1)
The MIRO trial is a prospective multicentre controlled
randomised phase III trial comparing HMIO (with
laparoscopic gastric mobilisation and open thoracotomy)
and open oesophagectomy (with open gastric mobilisa-
tion and thoracotomy) in patients with thoracic OC
who undergo oesophagectomy through the abdominal
and right-thoracic approach (Ivor-Lewis procedure). In
both arms of the study, patients will undergo an open-
right thoracic approach. After a complete preoperative
work-up and according to French national guidelines,
patients who are found to be eligible for an Ivor-Lewis
procedure (staged I, II or III, i.e., T1,T2,T3, N0 or N1,
M0) with or without neoadjuvant treatment will be con-
sidered eligible for inclusion in this study. The surgical
procedure will be scheduled 4 to 6 weeks after the com-
pletion of the neoadjuvant treatment, or within 4 weeks
following the preoperative work-up in cases of primary
surgery. Randomisation will be performed during the
surgical procedure after a laparoscopic exploration of
the abdominal cavity to confirm the absence of any con-
tra-indication for resection. Patients in arm A will
undergo HMIO, and patients in arm B will undergo tra-
ditional open oesophagectomy.
The primary endpoint is the major morbidity rate
occurring within 30 postoperative days, the two groups
will be compared regarding the postoperative course
and oncological outcomes.
Our primary hypothesis is that HMIO will reduce
major postoperative morbidity compared to the open
approach.
This study is planned for a 5-year duration with a 2-
year inclusion period and a 3-year follow-up period for
the last included patient. The results for the primary
endpoint will be available 1 month after the end of the
inclusion period.
2- Inclusion criteria
This study will include patients with squamous cell car-
cinoma (SCC) or adenocarcinoma (ADC) of the middle
or lower third of the oesophagus and who are eligible
for surgery.
The inclusion criteria are as follows: (i) patients with
S C Co rA D Co ft h et h o r a c i co esophagus staged I, II or
III (T1, T2, T3, N0 or N1, M0) before any treatment;
(ii) patients with OC in the middle or lower third or
junctional Siewert’s type I tumour; (iii) patients who
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Page 2 of 8are undergoing or not undergoing neoadjuvant radio-
therapy and/or chemotherapy; (iv) patients with
tumours deemed to be resectable with a curative intent
at the preoperative evaluation; (v) patients who are
over 18 and under 75 years of age; (vi) patients with
WHO status performance of 0, 1 or 2; (vii) patients
who provide a signed written consent form; (viii)
patients who can undergo one of the surgical modal-
ities to be investigated; and (ix) patients who will be
available for follow-up.
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Figure 1 Study flow chart.
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All patients who do not meet all the inclusion criteria
will be excluded. The other exclusion criteria are the
common contraindications for surgery related to patient
status, disease extension or operative technique.
The patient-associated exclusion criteria are patients
with the following features: (i) PaO2 < 60 mmHg, (ii) Pa
CO2 > 45 mmHg, (iii) FEV1 < 1000 ml/sec, (iv) cirrhosis,
(v) myocardial infarction or evolutive coronary artery dis-
ease, (vi) Leriche-Fontaine at stage II or more peripheral
arterial occlusive disease, (vii) weight loss exceeding 15%,
(viii) the presence of another malignant tumour within
the last 5 years or a synchronous malignant tumour, and
(ix) any other simultaneous experimental treatment.
The disease-associated exclusion criteria are (i)
another histological subtype of OC besides SCC or
ADC, (ii) tumours located at the pharyngoesophageal
junction, the cervical oesophagus, the upper third of the
oesophagus, or the oesophagogastric junction (types 2
or 3 of the Siewert’s classification), (iii) distant metas-
tases, including peritoneal carcinomatosis or metastasis
to the supra-clavicular and celiac lymph nodes, (iv)
recurrent nerve palsy, (v) tumoural involvement of adja-
cent mediastinal structures.
The surgical technique-associated exclusion criteria
are (i) contra-indication for laparoscopy and (ii) a his-
tory of supra-umbilical laparotomy.
4- Endpoints
The primary endpoint is the major pre- and postopera-
tive morbidity rate (occurring within 30 postoperative
days). Major pre- and postoperative morbidity is defined
as grade 2 (potentially life-threatening but not causing
residual disability and requiring medical or invasive pro-
cedures), grade 3 (causing residual disability, including
organ resection or persistence of life-threatening condi-
tions) and grade 4 (death as a result of complications)
surgical and medical complications, according to the
Dindo-Clavien classification [17]. The most severe com-
plications will be considered for the primary endpoint.
However, the total number of complications per patient
will also be monitored.
Secondary endpoints are postoperative mortality, post-
operative overall 30-day morbidity (major and minor),
the major pulmonary complication rate, disease-free sur-
vival (DFS: defined as the time interval between rando-
misation and the first recurrence (local, regional,
distant), second cancer or death), overall survival (OS:
defined as the time interval between randomisation and
all deaths), quality of life (evaluated using the EORTC
quality of life (QoL) questionnaires QLQ-C30 and QLQ-
OES18, and EuroQol 5D) and the global economic
impact of each surgical procedure.
A standardised definition of the main complications,
especially pulmonary complications, are as follows:
- anastomotic leakage, defined as a symptomatic (med-
iastinal abscess, mediastinitis or digestive flow in chest
drainage) or asymptomatic (diagnosed by water-soluble
contrast swallow or digestive endoscopy) disruption of
the intrathoracic anastomosis;
- gastric pull-up necrosis, defined as ischemia requir-
ing a surgical procedure and a partial or complete
removal of the gastric conduit;
- delayed gastric emptying, defined as iterative vomit-
ing after nasogastric tube removal (from day 5), despite
prokinetic treatment, requiring nasogastric tube re-
placement;
- recurrent laryngeal nerve palsy;
- major postoperative pulmonary complications are
defined as follows:
◦ major bronchic sputum, defined as bronchic spu-
tum with atelectasis requiring bronchoscopy and
lack of fever or hyperleukocytosis;
◦ pneumonia, defined as alveolo-interstitial radiologic
infiltration with the presence of at least two of the
following criteria: purulent sputum, temperature >
38.5°C or < 35°C or leukocytes > 10000/mm
3 or <
1500/mm
3;
◦ respiratory insufficiency, defined as the inability of
a patient to maintain a PaO2 > 60 mmHg or a
PaCO2 < 55 mmHg, requiring an oro-tracheal intu-
bation and assisted ventilation;
◦ t h ep r e s e n c eo fA c u t eR e s p i r a t o r yD i s t r e s sS y n -
drome (ARDS), defined as severe hypoxia (PaO2/
FiO2 < 200), diffuse bilateral pulmonary infiltration
and pulmonary wedge pressure less than 18 mmHg.
Acute lung injury, defined as PaO2/FiO2 between
200 and 300, is considered ARDS.
5- Randomisation
Patients will be randomised during the operative proce-
dure after performing a laparoscopic exploration of the
abdominal cavity to confirm the absence of contra-indi-
cations for surgery (hepatic cirrhosis, hepatic or perito-
neal metastasis, or non-resectable tumoural extension).
For patients in arm A, HMIO will be performed with
a laparoscopic gastric mobilisation followed by an open
thoracotomy. For patients in arm B, traditional open
oesophgectomy will be performed with open gastric
mobilisation through a midline laparotomy followed by
an open thoracotomy.
The randomisation will be performed using the strati-
fied block randomisation method (blocks of 4) for each
centre. A randomised list will be generated for each
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allocation during surgery according to serial inclusion.
6- Preoperative work-up
Patients with resectable OC will be considered to be
operable after a complete pre-therapeutic work-up,
which includes a physical examination, standard labora-
tory tests, an ear, nose and throat (ENT) examination, a
panendoscopy under general anaesthesia and a bronchial
fibroscopy with biopsies for SCC, an oesophagogastro-
duodenoscopy with biopsies and oesogastroduodenal
barium study, an ultrasound exploration of the cervical
and abdominal areas, a computed tomography (CT)
scan of the thorax, mediastinum and abdomen; an oeso-
phageal endoscopic ultrasound (EUS) examination, and
a positron emission tomography if required. Clinical
tumoural staging (cTNM) will be based on the data
obtained from CT scan, EUS and positron emission
tomography results.
7- Treatment methods
Perioperative procedures will be standardised indepen-
dently of the approach.
- Global preoperative care
For all patients in the study, we will (i) treat dental,
head and neck or bronchial infection, (ii) administer
Immunonutrition (Oral Impact
®, Nestlé Nutrition) 5 to
7 days prior to surgery, (iii) request cessation of smok-
ing and drinking for at least 1 month before surgery and
(iv) perform a percutaneous gastrostomy for artificial
nutrition for malnourished patients (more than 10% of
physical weight loss over a 6-month period).
- Anaesthesiology
Hydroxyzin (1 mg per kg) will be administered as a pre-
medication 2 hours before surgery. Patients will receive
standard monitoring. Two peripheral and one central
venous catheters will be placed. Arterial catheter place-
ment for continuous monitoring of the arterial blood
pressure is optional. A thoracic epidural analgesia will
be placed before induction of general anaesthesia. A test
injection of 2 ml of xylocain with 2% adrenalin will be
performed after the placement of the epidural catheter.
Induction of general anaesthesia will be performed with
intravenous injection of propofol (2 to 3 mg/kg), sufen-
tanil (0.2 to 0.3 μg/kg) and cis-astracurium (0.1 to 0.15
mg/kg). Patients will be intubated with a left double-
lumen endotracheal tube for single-lung ventilation dur-
ing the thoracic approach. Antibioprophylaxis will be
administered during induction with a second generation
cephalosporin. General anaesthesia will be maintained
with halogen gas (sevofluran or desfluran). Preoperative
analgesia will be based on administration of 5 to 10 ml
of 0.75% of ropivacain in the peridural catheter. During
the thoracic wound closure, a continuous perfusion of
0.2% ropivacain (6 to 8 ml/h) will be started. Myorelaxa-
tion will be obtained with intravenous boluses of cis-
atracurium (0.03 mg/kg) to maintain a maximum of two
responses to the train-of-four stimulation. Protective
ventilation will be performed with a small tidal volume
(8 ml/kg), a respiration frequency of 10 to 15 cycles/
min, an inspiration/expiration ratio of1/2, a FiO2 from
50 to 100%, and a positive end-expiratory pressure
around 5 cmH20. Ventilation will be adjusted to main-
tain PaCO2 between 35 and 40 mmHg, venous oxygen
saturation over 92% and a level of maximal pressure less
than 50 cmH2O. Intravenous administration of fluids
and electrolytes will be performed according to a rela-
tively restricted regimen with 4 to 5 ml/kg/h of Ringer
solution. Blood loss will be compensated by colloid
administration and, if necessary, red blood cell transfu-
sion to maintain haemoglobin levels from 7 to 10 g/dl.
Early extubation will be performed at the end of the
surgical procedure in normothermic patients.
- Surgical procedures
A laparoscopic exploration of the abdominal cavity is
mandatory in the two arms, before starting the Ivor-
Lewis procedure in order to confirm the absence of cir-
rhosis or metastatic diseases. If any contraindication to
surgery is found at this time, the patient will be consid-
ered as a screen failure. Otherwise, the patient will be
randomised between arm A and arm B. All patients will
undergo an Ivor-Lewis procedure with the same open
thoracic approach. The abdominal approach differs
between the two groups: HMIO with laparoscopic gas-
tric mobilisation will be used in arm A, and open gastric
mobilisation will be used in arm B. The surgical techni-
que has also been standardised. All patients will receive
a transthoracic en bloc esophagectomy with termino-lat-
eral anastomosis in the upper chest, including an
abdominal lymphadenectomy (left and right paracardial
regions along the lesser curve of the left gastric artery
and celiac axis) and an extended en bloc mediastinal
lymphadenectomy (left recurrent and right subclavian,
paratracheal, subcarinal, left and right bronchial, lower
posterior mediastinum, para-aortic, para-oesophageal
lymph nodes and thoracic duct), i.e., an extended two-
field lymphadenectomy. The oesophagus will be
replaced by the stomach in all cases. For the laparo-
scopic abdominal surgical procedure, the first step is
port insertion (a 10-mm optic port at an equal distance
between the xyphoid and the umbilicus, a 12-mm port
at the umbilicus for the stapler, a 5-mm port at the
xyphoid for the retractor, two 5-mm bilateral subcostal
ports and another 5-mm port in the left flank).
For the open abdominal approach, a midline supra-
umbilical laparotomy will be performed.
Except for the approach, the abdominal surgical pro-
cedure will be the same in the two arms of the study.
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fully mobilised by preserving the right gastro-epiploic
arcade and dividing the short gastric vessels. The divi-
sion of the gastro-hepatic ligament allows for dissection
of the hiatus and the phreno-oesophageal membrane.
T h en o d a lt i s s u ea tt h el e f tg a s t r i ca r t e r yo r i g i nw i l lb e
dissected en bloc with the stomach and the left gastric
pedicle will be divided. The Kocher manoeuvre will be
performed. Division of the gastric lesser curve by an
endoscopic linear stapler will create a large gastric tube
with a final staple application for this section during the
thoracic step. Neither pyloromyotomy nor pyloroplasty
are recommended, and a feeding tube jejunostomy will
be inserted for preoperatively malnourished patients.
The thoracic approach is the same in the two arms of
the study. An open thoracotomy will be performed in
the 5
th intercostal space. An en bloc oesophagectomy
will be performed after division of the inferior pulmon-
ary ligament and division of the mediastinal pleura, up
to the level of the azygos vein, which will be cut after
ligation. The oesophagus, along with the perioesopha-
geal tissue and lymph nodes, will be circumferentially
mobilised with en bloc resection of the surrounding tis-
sues and nodes as described above. The division of the
oesophagus will be performed at the upper part of the
chest. A frozen section analysis is mandatory before
manually or mechanically performing the anastomosis.
A naso-gastric tube will be placed in the gastroplasty.
The chest will be closed after placement of chest drains.
- Postoperative care
The patients will be placed in an intensive care unit for
at least 24 hours. Auto-controlled epidural analgesia will
be performed with 0.2% ropivacain and 0.4 μg/ml sufen-
tanil with continuous administration from 6 to 8 ml/h
and a possibility for bolus every 20 or 30 minutes for 5
days. Analgesia will be completed using paracetamol,
nefopam, tramadol, ketamine and morphinics according
to the visual analogue scale. Thromboprophylaxis will
begin within 6 hours following the end of the surgical
procedure. During the first 24 postoperative hours,
intravenous fluids will be administered (1000 to 1500 ml
of 5% serum glucose). Fluid drainage quantity will be
compensated with colloids volume per volume. Mean
arterial pressure less than 65 mmHg or diuresis less
than 0.5 ml.kg-1.h-1 will be treated by modifications of
the epidural parameters, vasoactive agents or fluid
administration test. In the postoperative setting, patients
will receive a pulmonary physiotherapy course twice per
day with incitative spirometry, non-invasive ventilation
according to the PaO2 level, gastric pull-up aspiration
through a nasogastric tube for 5 days, vocal cord exami-
nation, proton pump inhibitors and prokinetics. Artifi-
cial nutrition will be administered until patients are able
to consume an oral diet of at least 60% of their needs
with a caloric intake of 25 to 30 kcal/kg/day. Oral intake
will be progressively introduced on day 6 after removal
of nasogastric tube if no anastomotic leakage is
suspected.
- Histological analysis
The following parameters will be analysed: histological
subtype, tumour size, tumoural differentiation, number
of analysed lymph nodes, number of involved lymph
nodes, pTNM stage according the 7th edition of the
TNM classification [18], vertical and lateral margins,
radicality of resection (R0, R1 or R2) and tumour regres-
sion grade if neoadjuvant treatment is performed.
8- Data collection and follow-up
The patients will be followed-up at 30 days after surgery
and every 6 months for 3 years. The follow-up protocol
includes a physical examination, a thoracoabdominal CT
scan every 6 months, a ENT examination once a year
and a bronchoscopy every two years for SCC and a
digestive endoscopy every two years. The quality of life
questionnaires QLQ-30 and QLQ-OES18 will be com-
pleted by the patient at each step of follow-up during
the 3 years. The EuroQol 5D is completed at 30 days
and 6 months after surgery.
9- Participating centres
To prevent institution bias, the participating centres are
required to be experienced (i) in OC surgery and (ii) in
laparoscopic gastric mobilisation with at least 25 proce-
dures performed before entering the trial. A technical
surgical video has been sent to each participating centre
in order to standardise surgical technique with, in
selected cases, surgical technical supervision by the prin-
cipal investigator (CM).
Thirteen French centres will participate in the study:
the Claude Huriez University Hospital in Lille, the
Croix-Rousse University Hospital in Lyon, the Ambroise
Paré University Hospital in Boulogne-Billancourt, the
Pessac University Hospital of Bordeaux, the Montsouris
Mutualist Institute in Paris, the University Hospital of
Clermont-Ferrand, the Sainte Marguerite University
Hospital in Marseille, the University Hospital in Stras-
bourg, the University Hospital of Toulouse, the Saint-
Louis University Hospital in Paris, the Louis-Mourier
University Hospital Paris and the Pontchaillou Univer-
sity Hospital in Rennes and the University Hospital of
Nîmes.
10- Statistical evaluation and sample size
The hypothesis of this phase III study is that the laparo-
scopic abdominal approach will reduce major postopera-
tive 30-day morbidity rate. Based on published literature
[3-9,11], we postulate that we will observe a reduction
of major morbidity from 45% in study arm B to 25% in
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using a bilateral alpha-type-one error of 5%, a power of
80% using chi-2 and a binomial approach, the sample
size required in each group is 98. Estimating that very
few patients will be lost to follow-up before the 30 days
follow-up required for analysis of the primary endpoint,
we must include 200 patients in this study, assuming a
maximum of only 4 patients lost to follow-up. The sta-
tistical analysis will be based on the intention-to-treat
principle for the primary endpoint. Included patients
will be analysed in their initial treatment arm as deter-
mined by treatment received and eligibility criteria. The
expected inclusion duration is 2 years.
The primary endpoint will be described using frequen-
cies and percentages with a 95% confidence interval
(95% CI), and it will be compared between the groups
using the Fisher exact test. Univariate and multivariate
logistic regressions will be done to take into account
potential cofounding effects for post-operative
morbidity.
Survival endpoints will be estimated using the Kaplan
Meier method and compared using the log-rank test
stratified by centre. The survival endpoints will be
described by their median values with a 95% CI. Follow-
up will be estimated using the reverse Kaplan Meier
method
Univariate and multivariate Cox analyses will be done
to calculate the Hazard Ratio with 95% CI. The Fraitly
model will be also used to take into account any effects
of the centre.
Quality of life will be longitudinally analysed based on
the time to definitive QoL deterioration [19]. The tar-
geted dimensions will be global health, pain, alimenta-
tion, fatigue and physical functioning. Due to
multiplicity, the p value for QoL will be 1%.
11- Ethics and safety
This study protocol was approved by the Institutional
Review Board, the Nord-Ouest II ethic committee on
March 2009 and the AFSSAPS (Agence Française de
Sécurité Sanitaire des Produits de Santé) on May 2009
under the registration number 2009-A00144-53. The
institutional promoter is the University Hospital of Lille,
France. The trial has been registered on ClinicalTrial.
gov website under the identification number NCT
00937456. This study received a grant from the French
National Cancer Institute (INCA) in 2008.
The study complies with the Declaration of Helsinki
rules and the principles of the Good Clinical Practices
guidelines. Informed consent will be obtained from each
patient in a written form prior to randomisation.
Patient safety and all potential threats to the patients
will be monitored every 6 months by an independent
data safety monitoring board (DSMB) and, additionally,
at the discretion of the DSMB or Promoter. The DSMB
also will evaluate the primary endpoint data. Qualified
personnel at the sponsor site will also meet every three
months to review safety data, including adverse events
and serious adverse events. Any information deemed to
potentially affect the safety of the trial will be brought
to the attention of the DSMB.
Discussion
Despite considerable improvements in OC staging,
patient selection and surgical results over recent dec-
ades, the overall complication rate and the pulmonary
complication rate in particular have remained high
[1,19]. Therefore, it is important to develop alternative
operative techniques that could achieve similar cure
rates but cause less morbidity and provide a better qual-
ity of life compared with oesophagectomy with two-field
lymphadenectomy based on the Ivor-Lewis procedure,
which is the gold standard for treating middle- and
lower-third thoracic OC.
The development of minimally invasive techniques,
including laparoscopy and/or thoracoscopy, is the most
important advance. The vast majority of published stu-
dies have aimed to demonstrate the feasibility of MIO
more than the benefits for patients, and inconclusive
results regarding the outcomes have been reported
[3-5]. At the present time, there has been no rando-
mised controlled trial evaluating the impact of MIO on
postoperative and oncological outcomes. A multi-centre
randomised trial (the TIME Trial) has recently been
designed to study the impact of MIO compared to open
oesophagectomy for cancer, but this proposal includes
multiple oesophageal resection techniques, leading to
potential bias [10].
We hypothesise that HMIO based on the laparoscopic
procedure and an open thoracic approach may provide
a significant decrease in major postoperative complica-
tions without leading to any negative impact on oncolo-
gical outcomes based on: (i) the lower expected rate of
pulmonary complications due to the less invasive nature
of the procedure and reduced deterioration of the venti-
latory mechanisms compared to the open procedure [3],
(ii) the ease of performance and reproducibility at spe-
cialised and non-specialised centres, (iii) the absence of
direct tumoural dissection, avoiding tumoural dissemi-
nation and (iv) applicability to a large number of
patients regardless of the tumoural stage or neoadjuvant
treatment administration.
For these reasons, we propose to test the hypothesis
that HMIO based on laparoscopic gastric mobilisation
and open thoracotomy can decrease major postoperative
morbidity without compromising oncological outcomes
through a large multicentre prospective randomised
controlled trial. Due to the importance of perioperative
Briez et al. BMC Cancer 2011, 11:310
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Page 7 of 8and intraoperative procedures with respect to postopera-
tive outcomes, we have standardised these techniques, as
well as the definition of postoperative complications
among, the participating centres.
This randomised trial may provide a high level of evi-
dence supporting the use of HMIO in OC surgical man-
agement, as the laparoscopic procedure is considered a
simple, safe, reproducible and effective technique
worldwide.
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